Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABHD18 modifier
- Development stage
- Preclinical
- Lead developer
- Scenic Biotech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ABHD18 modifier is an antisense oligonucleotide (ASO) therapeutic candidate being developed by Scenic Biotech for the treatment of cardiomyopathy. The drug is designed to target and modulate the expression of ABHD18 (Abhydrolase Domain Containing 18), a protein identified as a potential genetic modifier in heart disease. By utilizing ASO technology, the program aims to alter the disease course in patients with cardiomyopathy. It is currently in the development stage.
- Other names
- ABHD18 ASOABHD-18 ASOABHD 18 ASOScenic Biotech-ABHD18-ASO-Cardiomyopathy
02
Targets
ABHD18 (Abhydrolase domain-containing protein 18)
Beyond the preview
Go deeper on ABHD18 modifier.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABHD18 modifier.